Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Sana Biotechnology, Inc. has received a consensus rating of "Buy" from seven analysts, with an average price target of $7.50.
• The company reported earnings of ($0.16) per share for its last quarter, surpassing analysts' expectations of ($0.20) by $0.04.
• A majority of institutional investors own Sana Biotechnology, with 88.23% of the stock held by them and significant stake increases reported from several large investors.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has earned a consensus rating of "Buy" from the seven analysts that are covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report on the stock in the last year is $7.50.

A number of research firms have recently weighed in on SANA. Wedbush began coverage on shares of Sana Biotechnology in a research report on Wednesday, September 24th. They set an "outperform" rating and a $5.00 price target for the company. Morgan Stanley began coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price target for the company. Finally, JMP Securities reissued a "market outperform" rating and set a $5.00 price target on shares of Sana Biotechnology in a research report on Tuesday, June 24th.

Sana Biotechnology Trading Up 6.0%

SANA stock opened at $3.54 on Tuesday. Sana Biotechnology has a twelve month low of $1.26 and a twelve month high of $7.30. The company has a market capitalization of $841.85 million, a P/E ratio of -3.34 and a beta of 1.88. The firm has a 50 day simple moving average of $3.53 and a 200-day simple moving average of $2.76.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04. On average, research analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several large investors have recently added to or reduced their stakes in the company. Marex Group plc bought a new stake in Sana Biotechnology in the second quarter valued at $10,423,000. Corient Private Wealth LLC lifted its stake in Sana Biotechnology by 264.7% in the second quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company's stock valued at $3,101,000 after buying an additional 824,505 shares during the last quarter. AQR Capital Management LLC lifted its stake in Sana Biotechnology by 136.7% in the second quarter. AQR Capital Management LLC now owns 1,356,363 shares of the company's stock valued at $3,703,000 after buying an additional 783,217 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Sana Biotechnology in the second quarter valued at $1,916,000. Finally, Millennium Management LLC lifted its stake in Sana Biotechnology by 604.8% in the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after buying an additional 625,481 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.